Bristol-Myers Squibb Receives High Marks from Gurus

Bristol-Myers Squibb CO (BMY) shines in guru report as it rates 87% using the Multi-Factor Investor model. The strong rating signals solid potential for the stock as investors focus on its low volatility and strong momentum.

Date: 01-01-2025

AI Rating: 7

Earnings Per Share (EPS): No information provided in the report. Revenue Growth: No information provided in the report. Net Income: No information provided in the report. Profit Margins: No information provided in the report. Free Cash Flow (FCF): No information provided in the report. Return on Equity (ROE): No information provided in the report. The report outlines that Bristol-Myers Squibb achieves a high score of 87% using the Multi-Factor Investor model, which focuses on factors such as low volatility, strong momentum, and high net payout yields. A score above 80% indicates interest in the stock, suggesting that the fundamentals showcase strength, although no specific metrics like EPS or net income were disclosed. The analysis includes a summary of the stock's performance against key criteria indicating a strong market cap and low volatility, which contribute positively to its valuation and investor sentiment. However, the lack of specific financial figures leaves a gap in understanding the stock's financial health. In conclusion, while the report reflects positively on Bristol-Myers Squibb's positioning within the market and indicates that it meets several investment criteria, the absence of detailed financial metrics like revenue growth and profit margins limits a thorough evaluation. Investors should consider both the high ratings and the missing data when making investment decisions regarding BMY.

Stocks: BMY